Business Wire

Technology Innovation Institute Announces Launch of NOOR, the World’s Largest Arabic NLP Model

Share

Technology Innovation Institute (TII), a global research center and applied research pillar of Abu Dhabi’s Advanced Technology Research Council, today announced the launch of NOOR, the world’s largest Arabic natural language processing (NLP) model to date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Noor, the world's largest Arabic NLP Model - AI Cross-Center Unit, Technology Innovation Institute (Photo: AETOSWire)

TII’s team of advanced researchers and Artificial Intelligence (AI) specialists, has joined forces with LightOn, a technology company that unlocks extreme-scale machine intelligence for businesses, to transform the Arabic NLP model. The NOOR model has the capability to carry out tasks beyond the domain of language - offering end-to-end pipeline high quality data, including crawling, filtering, and curation at scale. The model facilitates extreme-scale distributed training and serving – to deliver applications with efficient inference and model specialization.

Dr. Ray O. Johnson, CEO, TII and ASPIRE, said: “With this development, we are well on track to enhance our research capabilities and credentials as well as elevate the status of Abu Dhabi and the UAE as a serious research ecosystem. Our expert teams have demonstrated yet again that this region can achieve breakthrough R&D outcomes to impact the world.”

Dr. Ebtesam Almazrouei, Director, AI Cross-Center Unit, TII, said: “Large language models have taken the world of natural language processing by storm, and we are proud to introduce this cutting-edge model with 10 billion parameters - the world’s largest Arabic NLP model. The uniquely large Arabic dataset collected to train the model is the result of months of work that included curating, scrapping, and filtering of varied sources. A special thank you to the entire team that worked on this project to make NOOR the go-to exploration model in Arabic for academicians and businesses everywhere.”

Speaking on the launch, Prof. Mérouane Debbah, Chief Researcher, Digital Science Research Center and AI Cross-Center Unit, TII, said: “With NOOR, TII has expanded the scope of the modern standard Arabic model by leveraging know-how in large language models to build cross-disciplinary, cutting-edge expertise in this new generation of AI research.”

To curate the world’s largest high-quality cross-domain Arabic datasets, NOOR’s unique dataset of more than 30 billion words combines web data with books, poetry, news articles, and technical information to significantly widen the applicability of the model.

Dr. Ebtesam Almazrouei said the NOOR model is based on the popular Transformer architecture. As a decoder-only model, similar in structure to GPT-3, it is programmed to tackle generative tasks with architecture upgraded to reflect the latest developments in the world of machine learning, including improvements such as better positional embeddings. To help ensure quality at scale in the NOOR dataset, the TII team designed an automated filtering pipeline based on machine learning techniques. These tools identify text like quality references and safeguard the model from exposure to spam content.

Leveraging state-of-the-art 3D parallelism, NOOR was trained on a High-Performance Computing resource with 128 A100 GPUs, allowing for the distribution of computations and ensuring efficient use of the available hardware resources.

The Director of the AI Cross-Center Unit noted that this was only the first step in the Unit’s efforts to contribute to the wider UAE Strategy for Artificial Intelligence.

Named for the Arabic word "light", the model has been so called to establish the correlation of the Arabic language model to enlightening the mind.

About Technology Innovation Institute (TII)

For more information, visit www.tii.ae

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye